{"id":31286,"date":"2025-04-07T16:09:17","date_gmt":"2025-04-07T08:09:17","guid":{"rendered":"https:\/\/flcube.com\/?p=31286"},"modified":"2025-04-07T16:09:18","modified_gmt":"2025-04-07T08:09:18","slug":"bayers-vividion-therapeutics-starts-phase-i-study-for-ras-pi3k%ce%b1-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31286","title":{"rendered":"Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor"},"content":{"rendered":"\n

German pharmaceutical giant Bayer’s (ETR: BAYN<\/a>) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the initiation of a Phase I clinical study for its investigational RAS-PI3K\u03b1 inhibitor, VVD-159642. This marks a significant step forward in the development of targeted therapies for RAS-driven cancers.’<\/p>\n\n\n\n

Clinical Trial Details<\/strong>
The Phase I study (NCT06804824) is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-159642. The trial will assess the drug both as a single agent and in combination with sotorasib or trametinib in patients with advanced solid tumors.<\/p>\n\n\n\n

Therapeutic Potential<\/strong>
VVD-159642 represents a novel approach to targeting the RAS pathway, which is frequently mutated in various cancers. By inhibiting both RAS and PI3K\u03b1, the drug aims to enhance therapeutic efficacy and overcome resistance mechanisms commonly observed in RAS-driven malignancies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

German pharmaceutical giant Bayer’s (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the…<\/p>\n","protected":false},"author":1,"featured_media":31289,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,16,62,967,3973],"class_list":["post-31286","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-cancer","tag-clinical-trial-approval-initiation","tag-etr-bayn","tag-vividion-therapeutics"],"yoast_head":"\nBayer's Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical giant Bayer's (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the initiation of a Phase I clinical study for its investigational RAS-PI3K\u03b1 inhibitor, VVD-159642. This marks a significant step forward in the development of targeted therapies for RAS-driven cancers.'\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31286\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer's Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical giant Bayer's (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the initiation of a Phase I clinical study for its investigational RAS-PI3K\u03b1 inhibitor, VVD-159642. This marks a significant step forward in the development of targeted therapies for RAS-driven cancers.'\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31286\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T08:09:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-07T08:09:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0706-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31286#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31286\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor\",\"datePublished\":\"2025-04-07T08:09:17+00:00\",\"dateModified\":\"2025-04-07T08:09:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31286\"},\"wordCount\":150,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31286#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0706-png.webp\",\"keywords\":[\"Bayer\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"ETR: BAYN\",\"Vividion Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31286#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31286\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31286\",\"name\":\"Bayer's Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31286#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31286#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0706-png.webp\",\"datePublished\":\"2025-04-07T08:09:17+00:00\",\"dateModified\":\"2025-04-07T08:09:18+00:00\",\"description\":\"German pharmaceutical giant Bayer's (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the initiation of a Phase I clinical study for its investigational RAS-PI3K\u03b1 inhibitor, VVD-159642. This marks a significant step forward in the development of targeted therapies for RAS-driven cancers.'\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31286#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31286\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31286#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0706-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0706-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer's Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31286#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor - Insight, China's Pharmaceutical Industry","description":"German pharmaceutical giant Bayer's (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the initiation of a Phase I clinical study for its investigational RAS-PI3K\u03b1 inhibitor, VVD-159642. This marks a significant step forward in the development of targeted therapies for RAS-driven cancers.'","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31286","og_locale":"en_US","og_type":"article","og_title":"Bayer's Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor","og_description":"German pharmaceutical giant Bayer's (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the initiation of a Phase I clinical study for its investigational RAS-PI3K\u03b1 inhibitor, VVD-159642. This marks a significant step forward in the development of targeted therapies for RAS-driven cancers.'","og_url":"https:\/\/flcube.com\/?p=31286","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-07T08:09:17+00:00","article_modified_time":"2025-04-07T08:09:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0706-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31286#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31286"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor","datePublished":"2025-04-07T08:09:17+00:00","dateModified":"2025-04-07T08:09:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31286"},"wordCount":150,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31286#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0706-png.webp","keywords":["Bayer","Cancer","Clinical trial approval \/ initiation","ETR: BAYN","Vividion Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31286#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31286","url":"https:\/\/flcube.com\/?p=31286","name":"Bayer's Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31286#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31286#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0706-png.webp","datePublished":"2025-04-07T08:09:17+00:00","dateModified":"2025-04-07T08:09:18+00:00","description":"German pharmaceutical giant Bayer's (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the initiation of a Phase I clinical study for its investigational RAS-PI3K\u03b1 inhibitor, VVD-159642. This marks a significant step forward in the development of targeted therapies for RAS-driven cancers.'","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31286#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31286"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31286#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0706-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0706-png.webp","width":1080,"height":608,"caption":"Bayer's Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31286#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3K\u03b1 Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0706-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31286"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31286\/revisions"}],"predecessor-version":[{"id":31290,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31286\/revisions\/31290"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31289"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}